Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer - PubMed (original) (raw)
. 1998 Jul 9;394(6689):203-6.
doi: 10.1038/28212.
Affiliations
- PMID: 9671307
- DOI: 10.1038/28212
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
I Versteege et al. Nature. 1998.
Abstract
Malignant rhabdoid tumours (MRTs) are extremely aggressive cancers of early childhood. They can occur in various locations, mainly the kidney, brain and soft tissues. Cytogenetic and molecular analyses have shown that the deletion of region 11.2 of the long arm of chromosome 22 (22q11.2) is a recurrent genetic characteristic of MRTs, indicating that this locus may encode a tumour suppressor gene. Here we map the most frequently deleted part of chromosome 22q11.2 from a panel of 13 MRT cell lines. We observed six homozygous deletions that delineate the smallest region of overlap between the cell lines. This region is found in the hSNF5/INI1 gene, which encodes a member of the chromatin-remodelling SWI/SNF multiprotein complexes. We analysed the sequence of hSNF5/INI1 and found frameshift or nonsense mutations of this gene in six other cell lines. These truncating mutations of one allele were associated with the loss of the other allele. Identical alterations were observed in corresponding primary tumour DNAs but not in matched constitutional DNAs, indicating that they had been acquired somatically. The observation of bi-allelic alterations of hSNF5/INI1 in MRTs suggests that loss-of-function mutations of hSNF5/INI1 contribute to oncogenesis.
Similar articles
- Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations.
Sévenet N, Lellouch-Tubiana A, Schofield D, Hoang-Xuan K, Gessler M, Birnbaum D, Jeanpierre C, Jouvet A, Delattre O. Sévenet N, et al. Hum Mol Genet. 1999 Dec;8(13):2359-68. doi: 10.1093/hmg/8.13.2359. Hum Mol Genet. 1999. PMID: 10556283 - Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.
Uno K, Takita J, Yokomori K, Tanaka Y, Ohta S, Shimada H, Gilles FH, Sugita K, Abe S, Sako M, Hashizume K, Hayashi Y. Uno K, et al. Genes Chromosomes Cancer. 2002 May;34(1):33-41. doi: 10.1002/gcc.10052. Genes Chromosomes Cancer. 2002. PMID: 11921280 - hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
Rousseau-Merck MF, Versteege I, Legrand I, Couturier J, Mairal A, Delattre O, Aurias A. Rousseau-Merck MF, et al. Cancer Res. 1999 Jul 1;59(13):3152-6. Cancer Res. 1999. PMID: 10397258 - Molecular genetics of atypical teratoid/rhabdoid tumor.
Biegel JA. Biegel JA. Neurosurg Focus. 2006 Jan 15;20(1):E11. doi: 10.3171/foc.2006.20.1.12. Neurosurg Focus. 2006. PMID: 16459991 Review. - Integrase interactor 1 in health and disease.
Das S. Das S. Curr Protein Pept Sci. 2015;16(6):478-90. doi: 10.2174/1389203716666150316115156. Curr Protein Pept Sci. 2015. PMID: 25772157 Review.
Cited by
- Case report: long-term survival of an infant syndromic patient affected by atypical teratoid-rhabdoid tumor.
Modena P, Sardi I, Brenca M, Giunti L, Buccoliero AM, Pollo B, Biassoni V, Genitori L, Antonelli M, Maestro R, Giangaspero F, Massimino M. Modena P, et al. BMC Cancer. 2013 Mar 5;13:100. doi: 10.1186/1471-2407-13-100. BMC Cancer. 2013. PMID: 23510391 Free PMC article. - ARID1A mutations in cancer: another epigenetic tumor suppressor?
Wu JN, Roberts CW. Wu JN, et al. Cancer Discov. 2013 Jan;3(1):35-43. doi: 10.1158/2159-8290.CD-12-0361. Epub 2012 Dec 3. Cancer Discov. 2013. PMID: 23208470 Free PMC article. Review. - Prognostic factors and survival in non-central nervous system rhabdoid tumors.
Farber BA, Shukla N, Lim II, Murphy JM, La Quaglia MP. Farber BA, et al. J Pediatr Surg. 2017 Mar;52(3):373-376. doi: 10.1016/j.jpedsurg.2016.08.017. Epub 2016 Aug 31. J Pediatr Surg. 2017. PMID: 27639430 Free PMC article. - Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5.
Mora-Blanco EL, Mishina Y, Tillman EJ, Cho YJ, Thom CS, Pomeroy SL, Shao W, Roberts CW. Mora-Blanco EL, et al. Oncogene. 2014 Feb 13;33(7):933-8. doi: 10.1038/onc.2013.37. Epub 2013 Feb 25. Oncogene. 2014. PMID: 23435428 Free PMC article. - The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M, Jürgens H, Kool M, Görlich D, Eveslage M, Jung M, Meisterernst M, Frühwald M. Kerl K, et al. BMC Cancer. 2013 Jun 13;13:286. doi: 10.1186/1471-2407-13-286. BMC Cancer. 2013. PMID: 23764045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials